story of the week
Sapanisertib + Exemestane or Fulvestrant for HR-Positive/HER2-Negative Advanced/Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sapanisertib Plus Exemestane or Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Clin. Cancer Res 2021 Apr 05;[EPub Ahead of Print], B Lim, DA Potter, MA Salkeni, P Silverman, TC Haddad, F Forget, A Awada, JL Canon, M Danso, A Lortholary, H Bourgeois, E Tan-Chiu, S Vincent, B Bahamon, KJ Galinsky, C Patel, R Neuwirth, EJ Leonard, JR DiamondFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.